A Phase 1 interventional study of Mycobacteriophage Muddy_HRMN0052 and Amikacin Injection in Non-Tuberculous Mycobacterial (NTM) Pneumonia and Mycobacterium Abscessus Infection, sponsored by Vancouver Coastal Health. Enrolling by invitation at 1 site in Canada. Open to female participants. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Vancouver Coastal Health · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Pneumonia with a site in Canada — 11 open to participants now, 13 under way, 4 of them phase 3. Pneumonia · Canada.
Among the 56 studies in Pneumonia with a site in Canada, this one is the 36th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 1, reaches primary completion later than 5 of the 12 other live ones, and was the 55th registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →11 of the 56 studies in Pneumonia with a site in Canada are open now. Recruiting first, the newest first:
Jeffrey Pernica · Sites in Canada
Ages 6 mo–18 yrs
AHS Cancer Control Alberta · Sites in Canada
Ages 18+
Todd C. Lee MD MPH FIDSA · Sites in Canada
Ages 18–100
Pfizer · Sites in Canada, United States, Argentina and 16 more countries
Ages 12+
University of Manitoba · Sites in Canada, United States, Brazil and 1 more country
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 14 · Phase 4 4
First in 2002; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1 is below the median of 128 across 978 interventional studies indexed under Pneumonia.
Median enrollment 201 across the 38 interventional studies, 727 across the 18 observational. Of the 36 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 56 have an industry lead sponsor. The 10 most frequent:
Vancouver Coastal Health is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Vancouver Coastal Health has 1 study filed under Pneumonia — fewer than ten, so there is no comparison to draw.
5 of the studies in Pneumonia with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT06124092St. Justine's HospitalOutcomes of Children After Hospitalization in Intensive Care Unit | 2027-03 |
| NCT07015801University of CalgaryCMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency | 2027-04 |
| NCT07228702Vancouver Coastal HealthBacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 56 studies in Pneumonia with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease
Hypothesis
Hypothesis: Mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with MABS will reduce infection burden and improve pulmonary disease.
Objectives:
Specific End Points (during and post treatment up to last clinical follow-up (>24month):
Information on the Investigational Product (Mycobacteriophage Muddy_HRMN0052):
Initial IV dosing of Mycobacteriophage Muddy_HRMN0052 for treatment of Mycobacterium abscessus should be 1mL containing 1 x 10\^9 PFU/mL to be given IV twice daily.
Inhalation:
Initial inhaled (by nebulization or aerosolization) dosing of Mycobacteriophage Muddy_HRMN0052 for treatment of Mycobacterium abscessus should be 1mL containing 1 x 10\^9 PFU/mL to be given inhaled twice daily. For inhaled use, Mycobacteriophage Muddy_HRMN0052 is supplied in the lyophilized form that enhances the stability during nebulization.
The treatment duration for both routes of administration is expected to be between 16 to 24 weeks at minimum with a possible extension up to 24 months if necessary, based upon clinical response.
Treatment Regimen and Duration:
Initial IV dosing for treatment of Mycobacterium abscessus with Mycobacteriophage Muddy_HRMN0052 should be 1mL containing 1 x 10\^9 PFU/mL to be given IV twice daily.
Initial inhaled dosing for treatment of Mycobacterium abscessus with Mycobacteriophage Muddy_HRMN0052 should be 1mL containing 1 x 10\^9 PFU/mL to be given inhaled twice daily.
The duration of treatment to be determined based on clinical response, but the recommended initial course of treatment is expected to be at least 16-24 weeks and used together with antimicrobial therapy targeted at the infecting organism recovered from the patient. The duration and start timing of IV and inhaled formulation will be guided by tolerance and clinical response with potential transition to single route as treatment progresses.
If the inhaled route of administration is not tolerated by the patient, as determined by a drop in FEV1 percent predicted (FEV1pp) of greater than 20% from baseline with the first dosage, and/or intolerable symptoms of cough or shortness of breath that are not relieved with bronchodilator (salbutamol) with the first dose, or if respiratory symptoms develop with later dosing that are deemed intolerable by the patient, then the treatment will revert to IV administration.
Concurrent with MUDDY phage treatment the following antibiotics will be use. Use of phage plus antibiotics is similar to prior reported human treatment of NTM disease with mycobacteriophages and in line with Antibacterial Resistance Leadership Group (ARLG) Phage Taskforce (U.S.) guidance. To balance effectiveness and toxicity risk two antibiotics that Mycobacterium abscessus has been demonstrated susceptible to will be used. Selection of drugs is also informed by tolerance during prior treatment. Alternate medications will be used if toxicity from first choice antibiotics encountered. Antibiotics/rationale are as follows, all doses are standard weight-based dosing:
Initial Regimen:
Alternate agents (use if toxicity/intolerance to initial regimen agents to ensure on 2 antibiotics throughout):
AMENDMENT May 30, 2026:
Additional antibiotics to be used guided by follow-up drug susceptibilty testing (stopping medications that may show acquired resistance) and allowing up to 6 potentially effective antibiotic agents may include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
This is an individual patient expanded access study specific to one individual based on tailor intervention (Mycobacteriophage)
Inclusion Criteria:
Exclusion Criteria:
Use of mycobacteriophage
Biological: Mycobacteriophage Muddy_HRMN0052 · Drug: Amikacin Injection · Drug: Clofazimine · Drug: Bedaquiline (B) · Drug: Linezolid (LZD) · Drug: Sulfamethoxazole/Trimethoprim · Drug: Imipenem + Cilastatin · Drug: Ceftaroline fosamil · Drug: Omadacycline Oral Tablet
In-vitro effective Mycobacteriophage Muddy\_HRMN0052 against specific strain of Mycobacterium abscessus ssp abscessuss
Amikacin 1000mg IV 3x/wk
Clofazimine 100mg PO OD
Bedaquiline 400mg PO OD x 2 weeks then 200mg PO 3x/wk (Alternate agent if toxicity/intolerance to amikacin or clofazimine to ensure on 2 antibiotics throughout)
Linezolid 600mg PO OD (dose reduce to 600mg PO 3x/wk if adverse effects)(Alternate agent if toxicity/intolerance to amikacin or clofazimine to ensure on 2 antibiotics throughout)
Drug pages: SulfamethoxazoleStudies of SulfamethoxazoleSulfamethoxazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TrimethoprimStudies of TrimethoprimTrimethoprim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Sulfamethoxazole/Trimethoprim 800/160mg PO BID (Alternate agent if toxicity/intolerance to amikacin or clofazimine to ensure on 2 antibiotics throughout)
Drug pages: ImipenemStudies of ImipenemImipenem pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CilastatinStudies of CilastatinCilastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Imipenem 1g IV Q12H
Ceftaroline 600mg IV Q12H
Omadacycline 300mg PO BID
Microbiologic: Response
1\. Sputum culture status: time (days) to durable sputum culture conversion (no mycobacterial growth on 3 sputum sample)
Time frame: 2 years
Microbiologic: Resistance development
MABS drug and phage resistance development on follow-up sputum cultures (on treatment and post)
Time frame: 2 years
Microbiologic: Neutralizing antibody status.
Detection of mycobacteriophage neutralizing antibodies on follow-up serology
Time frame: 2 years
Clinical: Symptoms
Pulmonary and systemic symptom report change using adapted global assessment of quality of life. This will be patient reported and scored at each clinical assessment as follows and in reference/comparison to last/most recent score (negative = worse, positive = improved): * 4 Markedly Improved ( \>75% improved quality of life) * 3 Much Improved (51-75% improved quality of life) * 2 Improved (25-50% improved quality of life) * 1 Slightly Improved (1-24% improved quality of life) 0 No Change * 1 Slightly Worse (1-24% reduced quality of life) * 2 Worse (25-50% reduced quality of life) * 3 Much Worse (51-75% reduced quality of life) * 4 Markedly Worse (\>75 % reduced quality of life)
Time frame: 2 year
Clinical: Sputum
sputum production volume change (patient report)
Time frame: 2 year
Clinical: Radiographic
Chest imaging response (CT scan) to treatment
Time frame: 2 year
Clinical: Pulmonary Function
Spirometry and full PFT changes on treatment
Time frame: 2 year
Clinical: Adverse effects
Adverse clinical and laboratory events (number and severity) on treatment
Time frame: 2 year
Clinical: Symptoms
Pulmonary and systemic symptom report change (Physicians Global Assessment to measure quality of life)
Time frame: 2 year
Plan to share: Undecided — Will depend on participant and institution agreement
Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.
Of 35 phase 1 interventional studies under Pneumonia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 34. This study's planned 21 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amikacin · Clofazimine · Bedaquiline · Linezolid · Sulfamethoxazole · Trimethoprim · Imipenem · Cilastatin · Ceftaroline · Omadacycline
Vancouver Coastal Health